- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.13: 3 residues within 4Å:- Chain A: Y.15, N.17, N.48
Ligand excluded by PLIPNAG.14: 4 residues within 4Å:- Chain A: N.107, T.109, N.110, V.112
Ligand excluded by PLIPNAG.15: 3 residues within 4Å:- Chain A: E.117, N.146, N.147
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain A: G.216, N.218
Ligand excluded by PLIPNAG.17: 4 residues within 4Å:- Chain A: N.264, E.265, N.266
- Chain B: K.542
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain A: F.313, N.315, T.317, Q.564
Ligand excluded by PLIPNAG.19: 3 residues within 4Å:- Chain A: D.323, N.327, L.355
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain A: N.600, T.602, E.603, Q.628
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain A: N.689
- Chain C: Y.776
Ligand excluded by PLIPNAG.22: 4 residues within 4Å:- Chain A: A.686, E.1052, K.1053, N.1054
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain B: Y.15, N.48
Ligand excluded by PLIPNAG.24: 6 residues within 4Å:- Chain B: N.107, T.109, N.110, V.111, V.112, F.139
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain B: N.146, N.147
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain B: N.218, T.220
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain B: N.266
- Chain C: K.542
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain B: N.315, P.563, Q.564
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain B: N.327
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain B: N.600, T.602, Q.628
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: I.774, Y.776
- Chain B: N.689
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: Q.875
- Chain B: A.686, E.1052, N.1054
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain C: Y.15, N.48
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain C: N.107, T.109, V.112
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: Q.100, N.147
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain C: T.93, N.218, T.220
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain C: N.266
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain C: N.315, Q.564
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain C: D.323, N.327
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain C: N.600, T.602, Q.628
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain B: Y.776
- Chain C: N.689
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain C: A.686, E.1052, N.1054
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yu, H. et al., Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun (2023)
- Release Date
- 2023-01-25
- Peptides
- Spike glycoprotein: ABC
Light chain of YB13-292 Fab: DFG
Heavy chain of YB13-292 Fab: EHI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
EF
LG
GE
FH
HI
D
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yu, H. et al., Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun (2023)
- Release Date
- 2023-01-25
- Peptides
- Spike glycoprotein: ABC
Light chain of YB13-292 Fab: DFG
Heavy chain of YB13-292 Fab: EHI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
EF
LG
GE
FH
HI
D